VEEV
Veeva Systems Inc.219.30
-0.80-0.36%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '26
Downplays CRM risks, boosts AI outlook
Q&A largely reaffirms prepared remarks' upbeat tone, downplaying CRM attrition risks from six top-20 pharmas opting out—no near-term revenue hit expected, with CRM now just 20% of revenue (down from 25%) and 2030 goals intact via diverse paths like Crossix growth. A rival EDC win drew as a one-off aberration, not a trend, amid strong clinical pipelines. Veeva AI reception proved strong, with agents slated for every app by 2026 to boost efficiency. Crossix shines as a 3-5 year driver on digital ad tailwinds. CRM stays healthy overall. Watch AI adoption, win-backs.
Key Stats
Market Cap
36.05BP/E (TTM)
42.75Basic EPS (TTM)
5.13Dividend Yield
0%Recent Filings
8-K
Veeva names new accounting officer
10-Q
Q2 FY2026 results
Veeva crushed Q2 FY2026 with total revenues up 16% y/y to $811M, subscription services surging 17% y/y to $682M on R&D Solutions strength. Operating income jumped 33% y/y to $241M while gross margin held steady at 75%; diluted EPS rose 24% y/y to $1.40, confirmed against 169K diluted shares. Cash swelled to $1.7B with $1.3B YTD operating cash flow; no debt. Settled IQVIA litigation in August 2025 with no damages paid. Markets stay brutally competitive.
8-K
Veeva Q3 revenues up 16%
10-Q
Q2 FY2026 results
Veeva Systems posted solid Q2 FY2026 results, with total revenues climbing 17% year-over-year to $789M, driven by 17% growth in subscription services to $659M—R&D Solutions up 21% while Commercial Solutions rose 13%. Gross margin held steady at 75%, but operating income jumped 18% to $196M despite a $31M litigation charge in G&A; net income rose 17% to $200M, yielding diluted EPS of $1.19 on 168K shares. Cash swelled to $1.9B with $1.1B YTD operating cash flow, no debt, and FCF not disclosed in the 10-Q. Subscription revenue skewed 59% North America, 28% Europe. Yet competition from Salesforce in CRM remains a key risk.
IPO
Website
Employees
Sector
Industry
CMHSF
COMPREHENSIVE HEALTHCARE SYS IN
0.35+0.00
DH
Definitive Healthcare Corp.
2.29-0.01
HCTI
Healthcare Triangle, Inc.
2.09-0.18
IIIV
i3 Verticals, Inc.
25.57+0.52
IQV
IQVIA Holdings, Inc.
221.68-1.95
SOPH
SOPHiA GENETICS SA
4.81+0.09
VASO
Vaso Corporation
0.17+0.00
VRNS
Varonis Systems, Inc.
33.16+0.16
VSEE
VSee Health, Inc.
0.45-0.02
WEAV
Weave Communications, Inc.
6.98+0.23